focus -WSS

focus

author：entertainment 2025-09-07 21:56:50 - browse：3

From left: Daphne Koller, CEO of Insitro, Vijay Pande of Andreessen Horowitz and scientist Derek Lowe speaking at STAT's Breakthrough Summit in San Francisco. Sarah Gonzalez for STAT

Artificial intelligence is a rapidly improving technology. But its progress in drug development faces an increasingly urgent threat: An unending stream of overheated marketing.

To read of AI’s feats in press releases is to learn of a miracle product on the verge of unraveling biology’s most enduring secrets. It can map molecules and accurately predict how they fit together on computer screens. All you need to get to a cure — as they say in infomercials — is act now!

“I am very worried about the hype,” said Daphne Koller, chief executive of the machine learning drug discovery company Insitro, said during STAT’s Breakthrough West Summit in San Francisco last week. “People think (the breakthrough) is going to happen tomorrow.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Drug repurposing or repositioning? The language matters

WSS

Stanford president's case begs question: Who takes blame?

Stanford president faces new allegations over 1999 paper

Novavax promises a turnaround & Lilly roils the obesity market

Novavax promises a turnaround & Lilly roils the obesity market

Awakening the world to the whoosh: A patient's crusade

Public funding for King Charles III and royals has been recalculated due to windfarm deal profits

focus

focus

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

focus

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

How one medical school became remarkably diverse

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Heart attack and stroke risk calculators need revising

Guidelines to prevent youth baseball injuries need more muscle

Guidelines to prevent youth baseball injuries need more muscle

Public funding for King Charles III and royals has been recalculated due to windfarm deal profits

Affirmative action in medical school literally saved lives

Novavax promises a turnaround & Lilly roils the obesity market

explore

The high cost of giving birth even with insurance

Mass General totes up its waste in a move to tackle climate change

As demand for Covid shots wanes, Moderna seeks its next success

Tesla recalling nearly 16,000 of its 2021

Vir antibody drug aimed at influenza A fails in clinical trial

Hospitals struggle to profit from CAR

explore

leisure time

leisure time

entertainment